STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Rhea-AI Summary
SOPHiA GENETICS and AstraZeneca Spain have expanded their HRD testing program in Spain to support the molecular diagnosis of ovarian cancer. The program aims to increase access to local testing for homologous recombination deficiency (HRD) throughout the country, with the goal of making vital testing available to thousands more patients. AstraZeneca Spain has named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain, offering the option for HRD testing to become available to more laboratories. The collaboration aims to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
News

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Rhea-AI Summary
AstraZeneca invests $300 million in a new facility in Rockville, MD to launch life-saving cell therapy platforms for cancer trials and future commercial supply, creating over 150 highly skilled jobs. The facility will focus on manufacturing T-cell therapies for clinical trials and may expand to support other disease areas. This investment aims to make next-generation cell therapy a reality, accelerating the company's ambition to meet patient demands. The facility will be located near the company's R&D center and within the booming life sciences corridor in Maryland, providing an attractive environment for talent recruitment. AstraZeneca is building a cell therapy portfolio to empower T-cells to fight cancer more effectively, including CAR-Ts targeting solid tumors and a pipeline of novel T-cell receptor therapies through Neogene Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
none
-
News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU granted Priority Review by the FDA for the treatment of HER2-positive solid tumors based on promising clinical trial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
News

ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's ENHERTU has been granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors. The Prescription Drug User Fee Act (PDUFA) date is May 30, 2024. The sBLA is being reviewed under the Real-Time Oncology Review (RTOR) program and Project Orbis. The application is based on results from the DESTINY-PanTumor02 trial and supported by additional ENHERTU data. If approved, ENHERTU will potentially be the first HER2 directed treatment and antibody drug conjugate to receive a tumor agnostic indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
News

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Rhea-AI Summary
AstraZeneca announces the commercial availability of AIRSUPRA, an FDA-approved rescue treatment for asthma, designed to treat symptoms and inflammation to prevent asthma attacks. AIRSUPRA contains a short-acting beta2-agonist (SABA) and an inhaled corticosteroid (ICS), approved based on the results from two Phase III trials. The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together, recommending combination SABA/ICS as a rescue option for adults with asthma regardless of ICS maintenance medication. AIRSUPRA is the only FDA-approved, as-needed SABA/ICS asthma rescue now available in the US. The press release also includes endorsements from a physician and CEO of the Asthma and Allergy Wellness Center, and the Vice President of US Respiratory & Immunology at AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
News

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

Rhea-AI Summary
AstraZeneca's IMFINZI in combination with TACE and bevacizumab has shown a significant improvement in progression-free survival for patients with hepatocellular carcinoma (HCC) eligible for embolization. The EMERALD-1 Phase III trial demonstrated a 23% reduction in the risk of disease progression or death, with a median PFS of 15 months compared to 8.2 months with TACE alone. The safety profile for IMFINZI plus TACE and bevacizumab was generally manageable and consistent with the known profile of each medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
News

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
clinical trial
-
News

Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers

Rhea-AI Summary
Turbine (AZN): Turbine, a leading biological simulation company, collaborates with AstraZeneca to identify resistance mechanisms in hematological cancers using its Simulated Cell™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

Rhea-AI Summary
Allorion Therapeutics (AZN) announces an exclusive option and global license agreement with AstraZeneca for a novel EGFR L858R allosteric inhibitor program, aiming to treat advanced EGFR-mutant non-small cell lung cancer. The agreement includes upfront and near-term payments of up to $40 million, additional milestone payments of over $500 million, and tiered royalties on net sales worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases. The acquisition will enrich AstraZeneca's pipeline with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, GC012F, with a transaction value of approximately $1.2bn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
acquisition

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $67.01 as of January 10, 2025.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 207.8B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#40 Ranked by Market Cap
#1616 Ranked by Dividends

AZN Stock Data

207.80B
3.10B
0.01%
16.77%
0.32%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge